ANI Pharma (ANIP) Tops Q1 EPS by 15c; Suspends FY20 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to ANI Pharma (ANIP) Tops Q1 EPS by 15c; Suspends FY20 Guidance

ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO

May 7, 2020 8:30 AM EDT

BAUDETTE, Minn., May 7, 2020 /PRNewswire/ --

For the first quarter 2020, ANI reports:

Net revenues of $49.8 million versus $52.9 million in 2019 GAAP net loss of $7.0 million and diluted GAAP loss per share of $0.59 Adjusted non-GAAP EBITDA of $17.6 million Adjusted non-GAAP diluted earnings per share of $1.04

Integrates Amerigen Pharmaceuticals, Ltd. portfolio

Launches five generic products increasing total commercialized product line to 60 product families

Appoints Patrick D. Walsh interim President and CEO

Suspends guidance for 2020

ANI Pharmaceuticals, Inc.... More